Tislelizumab Combined With Chemotherapy in the Cross-line Treatment of First-line Resistant Advanced Gastric Cancer
Clinical trial NCT05751265 · UNKNOWN
Trial details
- NCT number
- NCT05751265
- Sponsor
- Fujian Cancer Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-07-01
- Primary completion
- 2024-06-01
- Enrollment
- 39
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.